Humana Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Humana wird ein jährliches Gewinn- und Umsatzwachstum von 14.2% bzw. 4.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 16.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.2% betragen.
Wichtige Informationen
14.2%
Wachstumsrate der Gewinne
16.8%
EPS-Wachstumsrate
Healthcare Gewinnwachstum | 17.0% |
Wachstumsrate der Einnahmen | 4.3% |
Zukünftige Eigenkapitalrendite | 15.1% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 24 Jun 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Humana: Medicare Advantage Will Never Be As Profitable As It Was
Jun 23Humana (NYSE:HUM) Is Due To Pay A Dividend Of $0.885
Jun 20Humana (NYSE:HUM) Will Pay A Dividend Of $0.885
Jun 06Humana Is Set Up For Long-Term Success
Jun 05Humana (NYSE:HUM) Has Affirmed Its Dividend Of $0.885
May 21Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885
Apr 22Here's Why Humana (NYSE:HUM) Can Manage Its Debt Responsibly
Apr 20Humana: Where To Buy This
Apr 02Humana: This Year's Drop Might Have Created A Buying Opportunity
Mar 19Humana: A Golden Buying Opportunity As Fears Potentially Peaked
Feb 03Humana: The $300 Level Could Get Taken Out In The Near Future
Jan 25Humana: My Oh My, Another Strong Buy
Jan 14Humana: Buy This Powerful Dividend Growth Stock In The New Year
Jan 02Does Humana (NYSE:HUM) Have A Healthy Balance Sheet?
Dec 14Humana: Failed Merger And Other Reasons To Buy
Dec 11Humana: Upgrade To Buy
Oct 06Humana: Buy This Amazing Wealth Compounder Now, You'll Be Glad You Did
Sep 27We Think Humana (NYSE:HUM) Can Manage Its Debt With Ease
Aug 25Humana: Mr. Market Got This One Right
Aug 03Humana: Recent Selloff Might Present A Buying Opportunity
Jul 13Humana: Rising Medical Costs Should Be Temporary
Jun 28Humana: Margin Expansion Supported By Growing Memberships
Jun 12Humana (NYSE:HUM) Seems To Use Debt Rather Sparingly
May 26Humana Inc. (NYSE:HUM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Apr 13Humana Q4 2022 Earnings Preview
Jan 31Humana: Destined For A Long-Term Success
Jan 23Humana (NYSE:HUM) Could Easily Take On More Debt
Jan 13Humana receives $70.85B contract from Defense Health Agency
Dec 22Are Investors Undervaluing Humana Inc. (NYSE:HUM) By 34%?
Dec 20Humana: Top-Rated Medicare Advantage Insurer With Room To Grow
Nov 14Humana prices $1.23B debt offering
Nov 08Humana Q3 2022 Earnings Preview
Nov 01Humana expands partnership with Cohere Health on prior authorization services
Oct 24Humana announces major expansion of Florida Dental Network, benefits
Oct 17We Think Humana (NYSE:HUM) Can Manage Its Debt With Ease
Oct 10Humana Inc.'s (NYSE:HUM) Intrinsic Value Is Potentially 92% Above Its Share Price
Sep 21Humana adds 9%, highest in over two years, after lifting guidance
Sep 15Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 121,295 | 2,823 | 3,548 | 4,285 | 15 |
12/31/2025 | 115,241 | 2,329 | 3,006 | 3,557 | 20 |
12/31/2024 | 113,998 | 1,799 | 1,964 | 2,447 | 20 |
3/31/2024 | 109,243 | 1,991 | -3,241 | -2,283 | N/A |
12/31/2023 | 106,374 | 2,489 | 2,977 | 3,981 | N/A |
9/30/2023 | 102,351 | 3,015 | 5,009 | 5,988 | N/A |
6/30/2023 | 98,727 | 3,378 | 12,156 | 13,189 | N/A |
3/31/2023 | 95,642 | 3,115 | 9,907 | 10,972 | N/A |
12/31/2022 | 92,870 | 2,806 | 3,450 | 4,587 | N/A |
9/30/2022 | 91,485 | 2,807 | 8,385 | 9,618 | N/A |
6/30/2022 | 90,512 | 3,143 | 2,729 | 4,000 | N/A |
3/31/2022 | 87,495 | 3,035 | 2,080 | 3,401 | N/A |
12/31/2021 | 83,064 | 2,933 | 920 | 2,262 | N/A |
9/30/2021 | 82,201 | 2,673 | 1,400 | 2,641 | N/A |
6/30/2021 | 80,450 | 2,482 | 456 | 1,621 | N/A |
3/31/2021 | 78,888 | 3,722 | 3,266 | 4,328 | N/A |
12/31/2020 | 77,155 | 3,367 | 4,675 | 5,639 | N/A |
9/30/2020 | 74,388 | 4,153 | 4,970 | 5,868 | N/A |
6/30/2020 | 70,554 | 3,502 | 5,637 | 6,495 | N/A |
3/31/2020 | 67,716 | 2,614 | 4,073 | 4,862 | N/A |
12/31/2019 | 64,888 | 2,707 | 4,548 | 5,284 | N/A |
9/30/2019 | 62,761 | 2,550 | 3,757 | 4,439 | N/A |
6/30/2019 | 60,726 | 2,505 | 306 | 942 | N/A |
3/31/2019 | 58,740 | 1,758 | -1,234 | -617 | N/A |
12/31/2018 | 56,912 | 1,683 | 1,561 | 2,173 | N/A |
9/30/2018 | 55,933 | 1,512 | -989 | -405 | N/A |
6/30/2018 | 55,009 | 1,367 | 2,950 | 3,513 | N/A |
3/31/2018 | 54,284 | 1,824 | 2,996 | 3,532 | N/A |
12/31/2017 | 53,767 | 2,448 | N/A | 4,051 | N/A |
9/30/2017 | 53,456 | 1,863 | N/A | 4,189 | N/A |
6/30/2017 | 53,868 | 1,814 | N/A | 5,829 | N/A |
3/31/2017 | 54,341 | 1,475 | N/A | 5,639 | N/A |
12/31/2016 | 54,379 | 614 | N/A | 1,936 | N/A |
9/30/2016 | 54,862 | 1,116 | N/A | 5,046 | N/A |
6/30/2016 | 54,531 | 980 | N/A | 1,575 | N/A |
3/31/2016 | 54,256 | 1,100 | N/A | 1,263 | N/A |
12/31/2015 | 54,289 | 1,276 | N/A | 868 | N/A |
9/30/2015 | 53,256 | 1,320 | N/A | 724 | N/A |
6/30/2015 | 52,131 | 1,296 | N/A | 646 | N/A |
3/31/2015 | 50,621 | 1,209 | N/A | 1,054 | N/A |
12/31/2014 | 48,500 | 1,147 | N/A | 1,618 | N/A |
9/30/2014 | 46,359 | 972 | N/A | 1,409 | N/A |
6/30/2014 | 44,440 | 1,050 | N/A | 1,602 | N/A |
3/31/2014 | 42,539 | 1,126 | N/A | 1,975 | N/A |
12/31/2013 | 41,313 | 1,231 | N/A | 1,716 | N/A |
9/30/2013 | 40,683 | 1,453 | N/A | 1,937 | N/A |
6/30/2013 | 40,015 | 1,511 | N/A | -544 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HUMDas prognostizierte Gewinnwachstum (14.2% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: HUMDie Erträge des Unternehmens (14.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.8% pro Jahr).
Hohe Wachstumserträge: HUMDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: HUMDie Einnahmen des Unternehmens (4.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).
Hohe Wachstumseinnahmen: HUMDie Einnahmen des Unternehmens (4.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: HUMDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.2%).